Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched

Seonyoung Park1, Ah-Young Kim1,2, Hyeonseok Cho2

  • 1Department of Pharmaceutical Medicine and Regulatory Sciences, Colleges of Medicine and Pharmacy, Yonsei University, Incheon, South Korea.

BMC Cancer
|November 27, 2020
PubMed
Abstract